Comparison of two immunoassays for measurement of faecal calprotectin in detection of inflammatory bowel disease: Pre-analytical and diagnostic performance characteristics

Clinical Chemistry and Laboratory Medicine

Volumn 52, Issue 3, 2014, Pages 391-397

  Oyaerta, Matthijs ^a   Trouvéa, Charlotte ^b   Baert, Filip ^a   De Smet, Dieter ^b   Langlois, Michel ^b   Vanpoucke, Hilde ^b  

^a Laboratory of Clinical Biology   (Belgium)

^b Department of Laboratory Medicine AZ Sint Jan Brugge Oostende ^*  (Belgium)

Author keywords

Crohn's disease; Faecal calprotectin; Inflammatory bowel disease; Likelihood ratio; Ulcerative colitis

Indexed keywords

CALGRANULIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; EXTRACTION; FECES; FEMALE; HUMAN; IMMUNOAFFINITY CHROMATOGRAPHY; IMMUNOASSAY; INFLAMMATORY BOWEL DISEASE; INTERMETHOD COMPARISON; LABORATORY DEVICE; MAJOR CLINICAL STUDY; MALE; POINT OF CARE TESTING; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COLITIS, ULCERATIVE; CROHN DISEASE; DIAGNOSIS, DIFFERENTIAL; FECES; FEMALE; HUMANS; IMMUNOASSAY; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84896107943     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2013-0699     Document Type: Article

References (22)

1. Silicia B, Saro C. Inflammatory bowel diseases: a disease(s) of modern times? Is incidence still increasing. World J Gastroenterol 2008;14:5491-8.
2. Soon I, Molodecky N, Rabi D, Ghali W, Barkema H, Kaplan G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterol 2012;142:46-54.
3. Mattar MC, Lough D, Pishvaian MJ, Charabaty A. Current management of inflammatory bowel disease and colorectal cancer. Gastrointest Cancer Res 2011;4:53-61.
4. Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. J Clin Microbiol 2002;15:79-94.
5. Hommes DW, van Deventer SJ. Endoscopy in inflammatory bowel diseases. Gastroenterol 2004;126:1561-73.
6. Stange EF, Travis SP, Vermeire S, Reinisch W, Geboes K, Barakauskiene A, et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis 2008;2:1-23.
7. IBD working group of the ESPHGAN. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis -the Porto criteria. J Pediatr Gastroenterol Nutr 2005;41:1-7.
8. Stange EF, Travis SP, Vermeire S, Beglinger C, Kupcinskas L, Geboes K, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 2006;55:1-15.
9. Tibble J, Teahon K, Thjodleifsson B, Roseth A, Sigthorsson G, Bridger S, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000;47:506-13.
10. Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterol 2002;123:450-60.
11. Roseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 2004;39:1017-20.
12. Roseth AG, Fagerhol MK, Aadland E, Schjonsby H. Assessment of the neutrophil dominating protein calprotectin in feces: a methodologic study. Scand J Gastroenterol 1992;27:793-98.
13. Coorevits L, Baert FJ, Vanpoucke HJ. Faecal calprotectin: comparative study of the Quantum Blue rapid test and an established ELISA method. Clin Chem Lab Med 2008;46: 1275-80.
14. Website National Institute for Health and Care Excellence. Available from: http://www.nice.org.uk/nicemedia/live/13789/64001/64001.pdf. Accessed on July 19, 2013.
15. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997;32:920-4.
16. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasaziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for reporting of diagnostic accuracy. Clin Chem 2003;49:1-6.
17. Whitehead SJ, French J, Brookes MJ, Ford C, Gama R. Betweenassay variability of faecal calprotectin enzyme-linked immunosorbent assay kits. Ann Clin Biochem 2013;50:53-61.
18. von Roon AC, Karamountzos L, Purkayastha S, Reese EG, Darzi AW, Teare JP, et al. Diagnostic precision of faecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 2007;102:803-13.
19. Gisbert JP, McNichol AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis 2009;41:56-66.
20. van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. Br Med J 2010;341:c3369.
21. Sherwood R. Faecal markers of gastrointestinal inflammation. J Clin Pathol 2012;65:981-5.
22. Ayling R. New faecal tests in gastroenterology. Ann Clin Biochem 2012;49:44-54.